EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

A Systematic Review and Meta‐Analysis of Randomized Controlled Trials on the Benefits of Using Lactobacillus Supplements as an Adjunct Treatment for Helicobacter pylori Eradication

Asma Azam iD, Muhammad Abdul Muqtadir Qureshi iD, Hafiz Shahbaz Zahoor iD, Syeda Malaika Raza iD, Muhammad Mohsin Khan iD, Umaimah Naeem iD, Syed Atif iD, Abdul Waheed iD

MicrobiologyOpen · 2025-12 · 14 (6)

DOI: 10.1002/mbo3.70166 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift MicrobiologyOpen, online erschienen am 01.12.2025. Verfasst von Asma Azam und 7 weiteren Autor:innen. Beteiligte Einrichtung: Karachi Medical & Dental College, Karachi, Pakistan. Hauptthemen laut MEDLINE: Helicobacter Infections, Probiotics, Helicobacter pylori, Lactobacillus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Supplementing H. pylori treatment with probiotics like Lactobacillus has become an essential approach due to the possible adverse effects of antibiotic therapy and the need to increase overall eradication rates. Although several types of Lactobacillus strains as probiotics were efficient in treating H. pylori , their relative efficiency in treating H. pylori was uncertain. A survey of databases, including PubMed, Cochrane, Google Scholar, Scopus, and Clinicaltrials.gov , retrieved 52 Randomized Controlled Trials (RCTs), with 14 meeting the criteria for RCTs on Lactobacillus supplementation (LS) as an adjunct therapy compared to placebo in adult H. pylori patients. Analyses were conducted using RevMan5.3, Cochrane Risk of Bias Tool, Comprehensive Meta‐Analysis Software, and GRADEpro. Fourteen RCTs, including 2054 patients with more than ten different probiotics, were included in this analysis. The LS group showed significantly higher H. pylori eradication rates [RR = 1.04 (95% CI: 1.01, 1.07; p = 0.009; I 2 = 0%); (high certainty)], decreased AEs including vomiting [RR = 0.82 (95% CI: 0.48, 1.41; p = 0.48; I 2 = 19%); (high certainty)], diarrhea [RR = 0.45 (95% CI: 0.26, 0.80; p = 0.007; I ² = 55%); (high certainty)], abdominal pain [RR = 0.73 (95% CI: 0.28, 1.93; p = 0.53; I ² = 66%); (high certainty)], anorexia [RR = 0.79 (95% CI: 0.23, 2.64; p = 0.70; I ² = 0%); (high certainty)], constipation [RR = 1.02 (95% CI: 0.42, 2.50; p = 0.96; I ² = 0%); (high certainty)], rash [RR = 1.51 (95% CI: 0.57, 3.98; p = 0.41; I ² = 0%); (high certainty)], taste disturbance [RR = 0.64 (95% CI: 0.44, 0.92; p = 0.02; I ² = 51%); (moderate certainty)], and reduction of gastrointestinal symptoms including abdominal pain [SMD = −0.19 (95% CI: −0.46, 0.09; p = 0.18; I² = %); (moderate certainty)]. None of the included RCTs depicted a high risk of bias. Lactobacillus added to triple or quadruple therapy increased eradication rates, but improvements in adverse effects and gastrointestinal symptoms were not significant. Multiple different strains limited assessment of individual effectiveness, preventing firm conclusions about the specific impact of each Lactobacillus type.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsProbioticsHelicobacter pyloriLactobacillusDietary SupplementsHumansRandomized Controlled Trials as TopicTreatment OutcomeAnti-Bacterial AgentsAdult

Stichwörter der Autor:innen

adjunct therapyefficacyhelicobacter pylorilactobacillusplacebo

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Karachi Medical & Dental College, Karachi, Pakistan.
  • Quaid-e-Azam Medical College, Bahawalpur, Pakistan.
  • Jinnah Sindh Medical University, Karachi, Pakistan.
  • Mary Washington Family Medicine Residency Program, Fredericksburg, Virginia, USA.
  • Department of Family Medicine, Dignity Health Medical Group, Arizona.
  • Creighton University School of Medicine, Phoenix, Arizona, USA.

ORCID-Profile: Asma Azam, Muhammad Abdul Muqtadir Qureshi, Hafiz Shahbaz Zahoor, Syeda Malaika Raza, Muhammad Mohsin Khan, Umaimah Naeem, Syed Atif, Abdul Waheed

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Azam, A., Qureshi, M. A. M., Zahoor, H. S., Raza, S. M., Khan, M. M., Naeem, U., Atif, S., & Waheed, A. (2025). A Systematic Review and Meta‐Analysis of Randomized Controlled Trials on the Benefits of Using Lactobacillus Supplements as an Adjunct Treatment for Helicobacter pylori Eradication. MicrobiologyOpen, 14(6). https://doi.org/10.1002/mbo3.70166

Vancouver

Azam A, Qureshi MAM, Zahoor HS, Raza SM, Khan MM, Naeem U, et al. A Systematic Review and Meta‐Analysis of Randomized Controlled Trials on the Benefits of Using Lactobacillus Supplements as an Adjunct Treatment for Helicobacter pylori Eradication. MicrobiologyOpen. 2025;14(6). doi:10.1002/mbo3.70166

BibTeX
@article{Azam2025,
  author = {Azam, Asma and Qureshi, Muhammad Abdul Muqtadir and Zahoor, Hafiz Shahbaz and Raza, Syeda Malaika and Khan, Muhammad Mohsin and Naeem, Umaimah and Atif, Syed and Waheed, Abdul},
  title = {A Systematic Review and Meta‐Analysis of Randomized Controlled Trials on the Benefits of Using Lactobacillus Supplements as an Adjunct Treatment for Helicobacter pylori Eradication},
  journal = {MicrobiologyOpen},
  year = {2025},
  volume = {14},
  number = {6},
  doi = {10.1002/mbo3.70166}
}
Kostenlos starten →